NEW YORK, May 2, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") who purchased Cardiovascular Systems common stock between May 2, 2011 and April 30, 2013 (the "Class Period"). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Cardiovascular Systems and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On April 30, 2013 an article in the Wall Street Journal reported that, the U.S. attorney's office for the Eastern District of New York issued subpoenas requesting information from three companies, including Cardiovascular Systems, for trading in the companies' shares by investment companies controlled by the Company's directors. On this news announcement, shares of Cardiovascular Systems fell $0.63 or 3% to close at a $17.16 on April 30, 2013.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT: Robert S. Willoughby Pomerantz Grossman Hufford Dahlstrom & Gross LLP firstname.lastname@example.orgSource:Pomerantz Grossman Hufford Dahlstrom & Gross LLP